专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20070167493A1 Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof 审中-公开
标题翻译：用于治疗老化和糖尿病性血管并发症的新型化合物，其制备方法，其治疗和美容用途
公开(公告)号：US20070167493A1
公开(公告)日：2007-07-19
申请号：US11727909
申请日：2007-03-29
申请人： Alangudi Sankaranarayanan
发明人： Alangudi Sankaranarayanan
IPC分类号： A61K31/44
CPC分类号： C07D409/14 , C07D413/14
摘要： The invention discloses a new clause of a five membered heterocylic ring compounds of general formula I and its pharmaceutically or cosmetically acceptable salts, wherein R1, R2, R3, R4, R5, A, B, X and Y are as defined in the specification. The invention also discloses a process for preparation of these compound and their therapeutic and cosmetic applications particularly in the management of aging related and diabetic vascular complications. The compounds in question act by triple action of an AGE (Advanced Glycation Endproducts) breaker, AGE inhibitor and free radical scavenger which make them most suitable in different therapeutic and cosmetic applications. The invention also discloses pharmaceuticals and cosmetic compositions comprising these compounds and method of treatment of diseases caused by accumulation of AGE and/or free radicals in the body cells.
摘要翻译：本发明公开了通式I的五元杂环环化合物及其药学上或化妆品上可接受的盐的新条款，其中R1，R2，R3，R4，R5，A，B，X和Y如说明书中所定义。本发明还公开了一种制备这些化合物及其治疗和美容应用的方法，特别是用于治疗老化和糖尿病性血管并发症。所述化合物通过AGE（高级糖化终产物）破坏剂，AGE抑制剂和自由基清除剂的三重作用起作用，使其最适合于不同的治疗和美容应用。本发明还公开了包含这些化合物的药物和化妆品组合物以及治疗由身体细胞中AGE和/或自由基的积累引起的疾病的方法。

12. 发明授权

US07223777B2 Compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof 失效
标题翻译：用于治疗老化相关和糖尿病血管并发症的化合物，其制备方法，其治疗和美容用途
公开(公告)号：US07223777B2
公开(公告)日：2007-05-29
申请号：US10116135
申请日：2002-04-05
申请人： Alangudi Sankaranarayanan
发明人： Alangudi Sankaranarayanan
IPC分类号： A61K31/4439 , C07D401/04
CPC分类号： C07D409/14 , C07D413/14
摘要： The invention discloses a new clause of a five membered heterocylic ring compounds of general formula I and its pharmaceutically or cosmetically acceptable salts, wherein R1, R2, R3, R4, R5, A, B, X and Y are as defined in the specification. The invention also discloses a process for preparation of these compound and their therapeutic and cosmetic applications particularly in the management of aging related and diabetic vascular complications. The compounds in question act by triple action of an AGE (Advanced Glycation Endproducts) breaker, AGE inhibitor and free radical scavenger which make them most suitable in different therapeutic and cosmetic applications. The invention also discloses pharmaceuticals and cosmetic compositions comprising these compounds and method of treatment of diseases caused by accumulation of AGE and/or free radicals in the body cells.
摘要翻译：本发明公开了通式I的五元杂环环化合物及其药学上或化妆品上可接受的盐的新条款，其中R1，R2，R3，R4，R5，A，B，X和Y如说明书中所定义。本发明还公开了一种制备这些化合物及其治疗和美容应用的方法，特别是用于治疗老化和糖尿病性血管并发症。所述化合物通过AGE（高级糖化终产物）破坏剂，AGE抑制剂和自由基清除剂的三重作用起作用，使其最适合于不同的治疗和美容应用。本发明还公开了包含这些化合物的药物和化妆品组合物以及治疗由身体细胞中AGE和/或自由基的积累引起的疾病的方法。

13. 发明授权

US07138416B2 Compounds and therapeutic uses thereof 失效
标题翻译：化合物及其治疗用途
公开(公告)号：US07138416B2
公开(公告)日：2006-11-21
申请号：US10408276
申请日：2003-04-08
申请人： Alangudi Sankaranarayanan
发明人： Alangudi Sankaranarayanan
IPC分类号： A61K31/41 , A61K31/44 , A61K31/4015 , C07D277/06
CPC分类号： C07D401/12 , C07D207/16 , C07D277/06 , C07D403/06 , C07D417/06 , C07D417/12 , C07D417/14
摘要： The invention discloses a novel series of compound represented by general formula (I), its derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, pharmaceutically acceptable salts, and solvates wherein X, n, k, z, R1, R2, R3, R4, R5 and R6 are as defined in the specification that are useful in (i) normalizing elevated blood glucose levels in diabetics, (ii) treating disorders related to glucose intolerance and (iii) for scavenging free radicals in mammals.
摘要翻译：本发明公开了一种新的一系列由通式（I）表示的化合物，其衍生物，类似物，互变异构体，立体异构体，多晶型物，药学上可接受的盐和溶剂合物，其中X，n，k，z，R1，R2，R3，R4 R5和R6如说明书中所定义，可用于（i）使糖尿病患者的血糖水平升高，（ii）治疗与葡萄糖不耐受有关的疾病和（iii）对哺乳动物中的自由基进行清除。

14. 发明申请

US20060167113A1 Process for preparation of polymorphic form of sertraline hydrochloride 审中-公开
标题翻译：盐酸舍曲林多晶型物质的制备方法
公开(公告)号：US20060167113A1
公开(公告)日：2006-07-27
申请号：US10534358
申请日：2003-11-03
申请人： Sunil Nadkarni
发明人： Sunil Nadkarni
IPC分类号： A61K31/135
CPC分类号： C07C209/84 , C07C211/42
摘要： The invention discloses a process for preparation of sertraline salts particularly sertraline hydrochloride Form V by dissolving or suspending sertraline mandelate in a solvent, reducing the pH of the solution or the suspension and isolating salt of sertraline The invention also provides for a pharmaceutical composition comprising said sertraline salt as active ingredient
摘要翻译：本发明公开了一种通过将舍曲林扁桃酸盐溶解或悬浮在溶剂中来降低溶液或悬浮液的pH并分离舍曲林盐的舍曲林盐，特别是盐酸舍曲林盐酸盐形式V的方法本发明还提供包含所述舍曲林的药物组合物盐作为活性成分

15. 发明申请

US20030225102A1 Novel compounds and therapeutic uses thereof 失效
标题翻译：新型化合物及其治疗用途
公开(公告)号：US20030225102A1
公开(公告)日：2003-12-04
申请号：US10408276
申请日：2003-04-08
申请人： TORRENT PHARMACEUTICALS LTD.
发明人： Alangudi Sankaranarayanan
IPC分类号： A61K031/496 , A61K031/4545 , A61K031/454 , A61K031/421 , A61K031/426 , A61K031/401 , C07D417/02 , C07D413/02 , C07D43/02
CPC分类号： C07D401/12 , C07D207/16 , C07D277/06 , C07D403/06 , C07D417/06 , C07D417/12 , C07D417/14
摘要： The invention discloses a novel series of compound represented by general formula (I), 1 its derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, pharmaceutically acceptable salts, solvates wherein X, n, k, z, R1, R2, R3, R4, R5 and R6 are as defined in the specification that are useful in (i) normalizing elevated blood glucose levels in diabetes, (ii) treating disorders related to glucose intolerance and (iii) for scavenging free radicals of mammals. The invention also discloses pharmaceutically acceptable composition comprising these compounds, method for preparation of the compounds as defined above and method of treating mammals including human beings by administering an effective amount of said compounds to a subject in need thereof. The invention further discloses use of these compounds in the manufacture of a medicament useful for treatment of different disease conditions as stated above.
摘要翻译：本发明公开了一种新的一系列由通式（I）表示的化合物，其衍生物，类似物，互变异构体，立体异构体，多晶型物，药学上可接受的盐，溶剂化物，其中X，n，k，z，R 1，R 2，R 3， R5和R6如说明书中所定义的，其可用于（i）使糖尿病中升高的血糖水平正常化，（ii）治疗与葡萄糖不耐症相关的疾病，和（iii）清除哺乳动物的自由基。本发明还公开了包含这些化合物的药学上可接受的组合物，如上定义的化合物的制备方法和通过向有需要的受试者施用有效量的所述化合物来治疗哺乳动物包括人的方法。本发明还公开了这些化合物在制备用于治疗如上所述的不同疾病状况的药物中的用途。

16. 发明申请

US20030092744A1 Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof 失效
标题翻译：用于治疗老化相关和糖尿病血管并发症的新型化合物，其制备方法及其治疗用途
公开(公告)号：US20030092744A1
公开(公告)日：2003-05-15
申请号：US10214704
申请日：2002-08-09
申请人： TORRENT PHARMACEUTICALS LTD.
发明人： Alangudi Sankaranarayanan
IPC分类号： A61K031/44 , C07D213/56
CPC分类号： C07D213/77 , A61K31/4425 , A61K31/4436 , A61K31/444 , A61K45/06 , C07D213/82 , C07D213/87 , C07D409/14 , A61K2300/00
摘要： The invention discloses novel compounds of the pyridinium series useful for the management of diabetes and aging-related vascular complications, including kidney disease, nerve damage, atherosclerosis, retinopathy, dermatological disorders and discoloration of teeth, by breaking preformed AGE, of the general formula I, or pharmaceutically acceptable salts thereof, 1 wherein, R1, R2, R3, X and m are as defined in the specification. The invention also discloses, method for preparation of the novel compounds of the series and pharmaceutical composition having one or more compounds as defined above as active ingredients. The invention further discloses a method of treatment of a diabetic patient by administering the compounds as defined above, either singly or in combination with drugs for antidiabetic therapy.
摘要翻译：本发明公开了用于治疗糖尿病和衰老相关血管并发症的新颖化合物，其包括肾脏疾病，神经损伤，动脉粥样硬化，视网膜病变，皮肤病学和牙齿变色，通过破坏预先形成的AGE，通式I 或其药学上可接受的盐，其中R1，R2，R3，X和m如说明书中所定义。本发明还公开了制备该系列新化合物的方法和具有一种或多种如上所定义的化合物作为活性成分的药物组合物。本发明还公开了一种通过单独给药上述化合物或与用于抗糖尿病治疗的药物组合来治疗糖尿病患者的方法。

17. 发明授权

US2381261A X-ray film holder 失效
标题翻译： X光片夹
公开(公告)号：US2381261A
公开(公告)日：1945-08-07
申请号：US45650142
申请日：1942-08-28
申请人： SMITH CORP A O
发明人： COTA ALVIN F
IPC分类号： G03B42/02
CPC分类号： G03B42/028

18. 发明申请

US20150290146A1 PHARMACEUTICAL COMPOSITION OF TAPENTADOL FOR PARENTERAL ADMINISTRATION 有权
标题翻译： TAPENTADOL的药物组合物用于住院治疗
公开(公告)号：US20150290146A1
公开(公告)日：2015-10-15
申请号：US14439840
申请日：2012-11-01
申请人： TORRENT PHARMACEUTICALS LTD
发明人： Sunil Sadanand Nadkarni , Jaya Abraham , Kapil Khatri
IPC分类号： A61K31/137 , A61K9/19 , A61K9/10 , A61K9/127 , A61K9/00 , A61K9/14
CPC分类号： A61K31/137 , A61K9/0019 , A61K9/0024 , A61K9/10 , A61K9/127 , A61K9/14 , A61K9/1647 , A61K9/19 , A61K47/14 , A61K47/22 , A61K47/26 , A61K47/32 , A61K47/34 , A61K47/38 , A61K47/44
摘要： The present invention relates to a pharmaceutical composition of tapentadol for parenteral administration which provides prolonged release of tapentadol. Present invention also relates to the process of preparation of pharmaceutical composition of tapentadol for parenteral administration and its use in the treatment of pain.
摘要翻译：本发明涉及一种用于肠胃外给药的刺他佐他的药物组合物，其提供了他喷他多的延长释放。本发明还涉及用于肠胃外给药的他喷他多药物组合物的制备方法及其在治疗疼痛中的用途。

19. 发明授权

US07939102B2 Controlled release formulation of lamotrigine 有权
标题翻译：拉莫三嗪的控制释放制剂
公开(公告)号：US07939102B2
公开(公告)日：2011-05-10
申请号：US10452772
申请日：2003-06-02
申请人： Sunil Sadanand Nadkarni , Navin Vaya
发明人： Sunil Sadanand Nadkarni , Navin Vaya
IPC分类号： A61K9/26
CPC分类号： A61K9/2081 , A61K9/0056 , A61K9/5078 , A61K31/53
摘要： Rapidly disintegrating multiparticulate controlled release formulations of lamotrigine having an improved pharmacokinetic profile and improved patient compliance, and process of preparing the formulations. It provides better control of blood plasma levels than conventional tablet formulations that is administered once or more times a day.
摘要翻译：具有改善的药代动力学特征和改善的患者依从性的拉莫三嗪的快速分解的多颗粒控制释放制剂以及制备制剂的方法。它比一天一次或多次施用的常规片剂制剂更好地控制血浆水平。

20. 发明申请

US20040106802A1 Novel compounds and therapeutic uses thereof 审中-公开
标题翻译：新型化合物及其治疗用途
公开(公告)号：US20040106802A1
公开(公告)日：2004-06-03
申请号：US10721272
申请日：2003-11-26
申请人： TORRENT PHARMACEUTICALS LTD.
发明人： Alangudi Sankaranarayanan
IPC分类号： C07D277/04 , C07D263/02 , C07D233/02
CPC分类号： C07D401/12 , C07D207/16 , C07D277/06 , C07D403/06 , C07D417/06 , C07D417/12 , C07D417/14
摘要： The invention discloses a novel series of compound represented by general formula (I), 1 its derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, pharmaceutically acceptable salts, solvates wherein X, n, k, z, R1, R2, R3, R4, R5 and R6 are as defined in the specification that are useful in (i) normalizing elevated blood glucose levels in diabetes, (ii) treating disorders related to glucose intolerance and (iii) for scavenging free radicals of mammals. The invention also discloses pharmaceutically acceptable composition comprising these compounds, method for preparation of the compounds as defined above and method of treating mamnnals including human beings by administering an effective amount of said compounds to a subject in need thereof. The invention further discloses use of these compounds in the manufacture of a medicament useful for treatment of different disease conditions as stated above.
摘要翻译：本发明公开了一种新的一系列由通式（I）表示的化合物，其衍生物，类似物，互变异构体，立体异构体，多晶型物，药学上可接受的盐，溶剂化物，其中X，n，k，z，R 1，R 2，R 3， R5和R6如说明书中所定义的，其可用于（i）使糖尿病中升高的血糖水平正常化，（ii）治疗与葡萄糖不耐症相关的疾病，和（iii）清除哺乳动物的自由基。本发明还公开了包含这些化合物的药学上可接受的组合物，如上所定义的化合物的制备方法和通过向有需要的受试者施用有效量的所述化合物来治疗包括人的哺乳动物的方法。本发明还公开了这些化合物在制备用于治疗如上所述的不同疾病状况的药物中的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式